BCL2 and neoplasm: The pan-Bcl-2 inhibitor Obatoclax can sensitize hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with ICIs, for Obatoclax can sensitize T cell mediated killing by promoting T cell activation and the expression of effector cytokines in spleen and tumor [112].